In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


ThromboGenics creates new company around pediatric brain tumor candidate

This article was originally published in Scrip

Executive Summary

Following up on a decision first mentioned in an August 2014 business update, ThromboGenics has spun out a new company called Oncurious to develop the early clinical-stage oncology candidate TB-403. VIB, a Belgian life sciences institute, is also a partner in the new venture, and it is hoped that access to basic research at VIB will allow Oncurious to go on to build an oncology pipeline behind TB-403. ThromboGenics will be the majority shareholder.


Related Content


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts